Here's the US exclusivity data for lenacapvir.[1] There are two issues - patents, and US clinical trial exclusivity. The latter is only good for five years and

Here's the US exclusivity data for lenacapvir.[1] There are two issues - patents, and US clinical trial exclusivity. The latter is only good for five years and expires in 2027. Some of the patents have narrow claims. The one that expires in 2041 applies only to the use of this drug in patients with extensive previous treatment, not for use for prevention. It really is a new drug, so some of the other patents from 2022 will hold up. [1] https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215973&Appl_type=N https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.c...